Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CERO CERo Therapeutics	$8.37 -0.1%	$10.12	$6.71 ▼ $895.40	$3.23M	0.48	311,580 shs	39,207 shs
LPTX Leap Therapeutics	$0.35 +4.6%	$0.36	$0.22 ▼ $4.79	$14.50M	-0.28	1.84 million shs	227,757 shs
ME 23andMe	$0.50 -35.3%	$0.50	$0.53 ▼ $10.72	$13.36M	1.19	1.52 million shs	29.28 million shs
PMN Promis Neurosciences	$0.45 +2.3%	$0.49	$0.38 ▼ $2.22	$14.71M	-0.1	490,089 shs	1.28 million shs

A Guide To High-Short-Interest Stocks

MarketBeat's analysts have just released their top five short plays for July 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CERO CERo Therapeutics	-3.34%	-3.34%	+14.64%	-29.82%	-97.83%
LPTX Leap Therapeutics	+1.39%	+5.32%	-18.35%	-9.30%	-84.65%
ME 23andMe	0.00%	0.00%	0.00%	0.00%	-94.87%
PMN Promis Neurosciences	-15.38%	+8.83%	-15.30%	-28.34%	-79.34%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
CERO CERo Therapeutics	3.7886 of 5 stars	3.7	4.0	0.0	0.0	2.9	0.8	0.0
LPTX Leap Therapeutics	2.2237 of 5 stars	3.0	2.0	0.0	0.0	3.8	0.0	1.3
ME 23andMe	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
PMN Promis Neurosciences	3.0815 of 5 stars	3.5	4.0	0.0	0.0	2.4	0.8	1.3

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CERO CERo Therapeutics	3.33	Buy	$45.00	437.63% Upside
LPTX Leap Therapeutics	2.00	Hold	$3.38	864.29% Upside
ME 23andMe	1.00	Sell	N/A	N/A
PMN Promis Neurosciences	3.00	Buy	$4.33	862.96% Upside

Current Analyst Ratings Breakdown

Latest CERO, ME, PMN, and LPTX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
7/14/2025	PMN Promis Neurosciences	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$4.00
7/14/2025	PMN Promis Neurosciences	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$4.00
6/23/2025	CERO CERo Therapeutics	D Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Hold ➝ Strong-Buy
6/23/2025	CERO CERo Therapeutics	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Hold ➝ Buy	$30.00
5/30/2025	CERO CERo Therapeutics	D Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
5/30/2025	CERO CERo Therapeutics	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Hold
5/19/2025	CERO CERo Therapeutics	Maxim Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$60.00
5/12/2025	PMN Promis Neurosciences	Maxim Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$3.00
4/22/2025	CERO CERo Therapeutics	D Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
4/22/2025	CERO CERo Therapeutics	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy ➝ Buy	$220.00 ➝ $220.00

(Data available from 7/16/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CERO CERo Therapeutics	N/A	N/A	N/A	N/A	($41.98) per share	N/A
LPTX Leap Therapeutics	N/A	N/A	N/A	N/A	$0.91 per share	N/A
ME 23andMe	$208.78M	0.06	$0.54 per share	0.93	$2.34 per share	0.21
PMN Promis Neurosciences	N/A	N/A	N/A	N/A	$0.50 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CERO CERo Therapeutics	-$8.30M	N/A	0.00	∞	N/A	N/A	N/A	-199.71%	8/13/2025 (Estimated)
LPTX Leap Therapeutics	-$67.56M	-$1.70	N/A	N/A	N/A	N/A	-162.15%	-120.05%	8/11/2025 (Estimated)
ME 23andMe	-$666.70M	-$15.45	N/A	∞	N/A	-183.39%	-170.07%	-62.13%	N/A
PMN Promis Neurosciences	$2.78M	-$0.05	N/A	N/A	N/A	N/A	-186.19%	-98.56%	8/6/2025 (Estimated)

Latest CERO, ME, PMN, and LPTX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/11/2025	Q2 2025	LPTX Leap Therapeutics	-$0.29	N/A	N/A	N/A	N/A	N/A
5/15/2025	N/A	CERO CERo Therapeutics	N/A	-$31.80	N/A	-$1.59	N/A	N/A
5/13/2025	Q1 2025	LPTX Leap Therapeutics	-$0.38	-$0.37	+$0.01	-$0.37	N/A	N/A
5/12/2025	Q1 2025	PMN Promis Neurosciences	-$0.14	-$0.21	-$0.07	-$0.21	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
CERO CERo Therapeutics	N/A	N/A	N/A	N/A	N/A
LPTX Leap Therapeutics	N/A	N/A	N/A	N/A	N/A
ME 23andMe	N/A	N/A	N/A	N/A	N/A
PMN Promis Neurosciences	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CERO CERo Therapeutics	N/A	0.73	0.73
LPTX Leap Therapeutics	N/A	2.41	2.41
ME 23andMe	N/A	1.05	0.91
PMN Promis Neurosciences	N/A	3.36	3.36

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
CERO CERo Therapeutics	29.64%
LPTX Leap Therapeutics	30.46%
ME 23andMe	36.10%
PMN Promis Neurosciences	50.13%

Insider Ownership

Company	Insider Ownership
CERO CERo Therapeutics	12.72%
LPTX Leap Therapeutics	7.50%
ME 23andMe	26.32%
PMN Promis Neurosciences	6.11%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
CERO CERo Therapeutics	8	386,000	337,000	N/A
LPTX Leap Therapeutics	40	41.44 million	38.33 million	Optionable
ME 23andMe	770	26.83 million	19.77 million	Not Optionable
PMN Promis Neurosciences	5	32.69 million	30.69 million	Not Optionable

CERO, ME, PMN, and LPTX Headlines

Recent News About These Companies

HC Wainwright & Co. Initiates Coverage of ProMIS Neurosciences (PMN) with Buy Recommendation

July 15 at 8:48 PM | msn.com

ProMIS Neurosciences Presents at H.C. Wainwright 6th Annual Neuro Perspectives Hybrid Conference

June 17, 2025 | globenewswire.com

ProMIS Neurosciences Inc. Announces Completion of First Cohort in PRECISE-AD Trial for PMN310 in Alzheimer's Disease

May 13, 2025 | nasdaq.com

ProMIS Neurosciences Stock Price, Quotes and Forecasts | NASDAQ:PMN | Benzinga

May 13, 2025 | benzinga.com

ProMIS Neurosciences Announces First Quarter 2025 Financial Results

May 12, 2025 | globenewswire.com

ProMIS Neurosciences reports FY24 EPS 11c vs. ($1.07) last year

March 31, 2025 | markets.businessinsider.com

ProMIS Neurosciences Inc.: ProMIS Neurosciences Announces Full Year 2024 Financial Results and Recent Highlights

March 31, 2025 | finanznachrichten.de

ProMIS Neurosciences Announces Full Year 2024 Financial Results and Recent Highlights

March 31, 2025 | globenewswire.com

ProMIS Neurosciences Showcases Preclinical Data on Platform-Derived Antibody and Vaccines for Neurodegenerative Diseases at Alzheimer's Disease/Parkinson's Disease 2025 International Conference

March 24, 2025 | globenewswire.com

ProMIS Neurosciences Showcases Preclinical Data on Platform Derived Vaccines for Neurodegenerative Diseases at the American Academy of Neurology 2025 Annual Meeting

March 13, 2025 | globenewswire.com

ProMIS Neurosciences to Participate in the 37th Annual Roth Conference

March 11, 2025 | globenewswire.com

ProMIS Neurosciences Doses First Patients in Phase 1b PRECISE-AD Trial of PMN310 for Alzheimer’s Disease

February 25, 2025 | markets.businessinsider.com

ProMIS Neurosciences doses first patiets in Phase 1b PRECISE-AD trial

February 25, 2025 | markets.businessinsider.com

ProMIS Neurosciences Doses First Patients in Phase 1b PRECISE-AD Trial of PMN310 for Alzheimer's Disease

February 25, 2025 | globenewswire.com

ProMIS Neurosciences Separates With Gavin T. Malenfant as Chief Operating Officer

February 20, 2025 | marketwatch.com

ProMIS Neurosciences seperates from COO Malenfant, terminates COO position

February 20, 2025 | markets.businessinsider.com

ProMIS Neurosciences, Inc. (NASDAQ:PMN) Insider Neil Cashman Acquires 15,000 Shares

February 13, 2025 | insidertrades.com

ProMIS Neurosciences to Participate in Guggenheim Securities SMID Cap Biotech Conference

January 29, 2025 | financialpost.comF

ProMIS Neurosciences to Participate in Guggenheim Securities SMID Cap Biotech Conference

January 29, 2025 | financialpost.comF

ProMIS Neurosciences to Participate in Guggenheim Securities SMID Cap Biotech Conference

January 29, 2025 | globenewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

IPO Momentum Returns: 3 Stocks Rising After CoreWeave’s Surge
By Dan Schmidt | June 20, 2025
View IPO Momentum Returns: 3 Stocks Rising After CoreWeave’s Surge
3 AI Infrastructure Stocks With Strong Growth, Not Hype
By Chris Markoch | June 26, 2025
View 3 AI Infrastructure Stocks With Strong Growth, Not Hype
How a Government Loan Changes the Game for Plug Power
By Jeffrey Neal Johnson | July 4, 2025
View How a Government Loan Changes the Game for Plug Power
BigBear.ai: Why a 90% Rally Could Be Just the Start
By Jeffrey Neal Johnson | July 10, 2025
View BigBear.ai: Why a 90% Rally Could Be Just the Start
Don’t Miss These 2 Small Quantum Stocks Poised to Pop
By Gabriel Osorio-Mazilli | June 24, 2025
View Don’t Miss These 2 Small Quantum Stocks Poised to Pop

CERO, ME, PMN, and LPTX Company Descriptions

CERo Therapeutics NASDAQ:CERO

$8.37 -0.01 (-0.12%)

Closing price 04:00 PM Eastern

Extended Trading

$8.59 +0.22 (+2.63%)

As of 05:37 PM Eastern

CERo Therapeutics Holdings, Inc., an immunotherapy company, focuses on advancing the development of engineered T cell therapeutics for the treatment of cancer. Its lead program in hematologic malignancies targets an Eat Me signal upregulated on B cell and myeloid tumors. The company is based in South San Francisco, California.

Leap Therapeutics NASDAQ:LPTX

$0.35 +0.02 (+4.57%)

Closing price 04:00 PM Eastern

Extended Trading

$0.35 +0.00 (+0.57%)

As of 05:38 PM Eastern

Leap Therapeutics, Inc., a biopharmaceutical company, acquires and develops antibody therapies for the treatment of cancer. Its lead product candidates include DKN-01, a monoclonal antibody that inhibits Dickkopf-related protein 1, which is in multiple ongoing clinical trials for treating esophagogastric and gynecologic cancers; and FL-301, a monoclonal antibody that targets cells that express Claudin18.2 on their cell surface and is in phase II clinical trial, as well as two preclinical antibody programs, FL-302 and FL-501. Leap Therapeutics, Inc. has an option and license agreement with NovaRock, Adimab, and BeiGene, Ltd. to develop and commercialize DKN-01 in Asia (excluding Japan), Australia, and New Zealand. The company was formerly known as HealthCare Pharmaceuticals, Inc. and changed its name to Leap Therapeutics, Inc. in November 2015. Leap Therapeutics, Inc. was incorporated in 2011 and is based in Cambridge, Massachusetts.

23andMe NASDAQ:ME

23andMe Holding Co. operates as a consumer genetics testing company. The company operates in two segments, Consumer & Research Services and Therapeutics. The Consumer & Research Services segment provides a suite of genetic reports, including information on customers' genetic ancestral origins, personal genetic health risks, and chances of passing on certain rare carrier conditions to their children, as well as reports on how genetics can impact responses to medications. This segments also operates Lemonaid telehealth platform to access affiliated licensed healthcare professionals for medical consultation and treatment for various common conditions; and offers research services. The Therapeutics segment focuses on the drug development; and discovery and development of novel therapies to enhance patient lives across various therapeutic areas, including oncology, respiratory, and cardiovascular diseases, as well as offers out-licensing intellectual property associated with identified drug targets related to drug candidates under clinical development. The company's therapeutics product portfolio comprises 23ME-00610 (P006), a humanized monoclonal antibody, which is in phase 1/2a clinical trials to interfere with the ability of CD200R1 to interact with CD200 in cancer cells; and GSK6097608, an antibody that targets CD96 for attenuating T and NK cell anti-tumor immune responses. The company was incorporated in 2006 and is headquartered in South San Francisco, California.

Promis Neurosciences NASDAQ:PMN

$0.45 +0.01 (+2.27%)

Closing price 03:59 PM Eastern

Extended Trading

$0.43 -0.02 (-4.89%)

As of 05:39 PM Eastern

ProMIS Neurosciences, Inc. discovers and develops antibody therapies and therapeutic vaccines neurodegenerative diseases and other misfolded protein diseases in Canada. The company's proprietary discovery platform comprises ProMIS and Collective Coordinates algorithms to predict novel targets known as disease specific epitopes on the molecular surface of misfolded proteins. Its lead product candidates comprise of PMN310, a monoclonal antibody (mAb) for toxic oligomers in AD; PMN267, a TDP-43; and PMN442, a mAb targeting toxic a-syn oligomers and seeding fibrils. The company was formerly known as Amorfix Life Sciences Ltd. and changed its name to ProMIS Neurosciences, Inc. in July 2015. ProMIS Neurosciences, Inc. was incorporated in 2004 and is headquartered in Toronto, Canada.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time